Join us in-person for a KOL Event with Humacyte, featuring Michael Curi, MD, MPA (Rutgers New Jersey Medical School) and his patient Devin Barnett, who will discuss the recently announced top line clinical data from the Humacyte Phase 2/3 V005 trial, the unmet clinical need in vascular trauma, and the use of the Human Acellular Vessel (HAV) as a potential extremity repair solution.

The HAV is an off-the-shelf, universally implantable bioengineered human tissue, that is being studied in traumatic injury and other vascular diseases. The HAV has received priority designation for the treatment of vascular trauma by the U.S. Department of Defense and Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration.

A live question and answer session will follow the formal presentations.